TrkC
TrkC (NTRK3) is a receptor tyrosine kinase that functions as a high-affinity receptor for neurotrophin-3 (NT-3) and supports neurotrophin-dependent signaling in neural contexts[1]. Mechanistically, TrkC signaling connects ligand recognition to receptor activation and downstream biological responses, while developmental studies show broad expression in the developing nervous system and selected non-neuronal tissues[2]. In synapse models, postsynaptic TrkC interacts with presynaptic PTPσ to generate bidirectional adhesion and recruitment that are essential for excitatory synapse development[3]. In genetic mouse models, disruption of TrkC eliminates Ia muscle afferent projections, reduces large myelinated axons, and produces abnormal movement and posture, linking NT-3/TrkC signaling to proprioceptive circuit formation[4]. Compared with related Trk isoforms, TrkC shows key ligand and splice-isoform distinctions: TrkC is identified as an NT-3 receptor, and alternative TrkC isoforms display distinct biological properties and substrate specificities[1][5]. Kinase-insert TrkC isoforms show impaired signaling responses, emphasizing isoform selection as a critical experimental variable[6]. For research applications, selective TrkC peptidomimetics can function as agonistic ligands, while NT-3-derived peptidomimetics can antagonize TrkC activation and signaling[7][8].
References:
- [1]. Lamballe F, et al. trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell. 1991 Sep 6;66(5):967-79. [Content Brief]
- [2]. Tessarollo L, et al. trkC, a receptor for neurotrophin-3, is widely expressed in the developing nervous system and in non-neuronal tissues. Development. 1993 Jun;118(2):463-75. [Content Brief]
- [3]. Takahashi H, et al. Postsynaptic TrkC and presynaptic PTPσ function as a bidirectional excitatory synaptic organizing complex. Neuron. 2011 Jan 27;69(2):287-303. [Content Brief]
- [4]. Klein R, et al. Disruption of the neurotrophin-3 receptor gene trkC eliminates la muscle afferents and results in abnormal movements. Nature. 1994 Mar 17;368(6468):249-51. [Content Brief]
- [5]. Lamballe F, et al. trkC encodes multiple neurotrophin-3 receptors with distinct biological properties and substrate specificities. EMBO J. 1993 Aug;12(8):3083-94. [Content Brief]
- [6]. Tsoulfas P, et al. TrkC isoforms with inserts in the kinase domain show impaired signaling responses. J Biol Chem. 1996 Mar 8;271(10):5691-7. [Content Brief]
- [7]. Zaccaro MC, et al. Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities. Chem Biol. 2005 Sep;12(9):1015-28. [Content Brief]
- [8]. Brahimi F, et al. A peptidomimetic of NT-3 acts as a TrkC antagonist. Peptides. 2009 Oct;30(10):1833-9. [Content Brief]
-
TrkC Related Products (34)
Related Products (34)
- 1
- 2
-
Trk-IN-7
0 ImagesCat. No.: HY-143557CAS No.: 2383011-61-6
-
PTX-BD10-2
0 ImagesCat. No.: HY-148750CAS No.: 1627834-10-9Synonyms: BD10-2PTX-BD10-2 (BD10-2) is an orally active TrkB/C modulator. PTX-BD10-2 ameliorates BFCN degeneration. PTX-BD10-2 restores cholinergic neurite integrity, alleviates cholinergic neurite atrophy. PTX-BD10-2 can be used in the research of Alzheimer's disease.
-
Trk-IN-20
0 ImagesCat. No.: HY-150561CAS No.: 2460924-63-2
-
TRK-IN-23
0 ImagesCat. No.: HY-149965CAS No.: 2924344-29-4
-
TIY-7
0 ImagesCat. No.: HY-146755CAS No.: 2846435-83-2TIY-7 is a selective and orally active tropomyosin receptor kinase (TRK) inhibitor. TIY-7 shows enzyme inhibitory activity with IC50s of 2.9, 1.1, 0.7, 0.8, 0.8, 0.2 nM for TRKA, TRKAG595R, TRKAG667C, TRKAF589L, TRKCG623R, TRKCG696A, respectively. TIY-7 shows anti-tumor potency in mouse xenograft model.
-
TRK II-IN-1
0 ImagesCat. No.: HY-151945CAS No.: 2904690-41-9
-
JND4135
0 ImagesCat. No.: HY-126287CAS No.: 2366216-76-2JND4135 is a Type II TRK inhibitor with IC50 values of 2.79, 3.19, and 3.01 nM against TRKA, TRKB, TRKC, respectively. JND4135 can overcome resistance from TRK xDFG and other mutant forms in the BaF3 stable model, inhibiting phosphorylation of both WT and xDFG mutant TRKs, along with their downstream signaling molecules. JND4135 can induce G0/G1 phase arrest and apoptosis in BaF3–CD74-TRKA-G667C cells. JND4135 shows tumor growth inhibition activity in the BaF3-CD74-TRKA-G667C mouse xenograft model.
-
Pan-Trk-IN-3
0 ImagesCat. No.: HY-144069CAS No.: 2763637-66-5Pan-Trk-IN-3 (Compound 11g) is a potent inhibitor of pan-Trk and their drug-resistant mutants with IC50 values of 2, 3, 2, 21, 26, 5, 7 and 6 nM against TrkA, TrkB, TrkC, TrkAG595R, TrkAG667C, TrkAG667S, TrkAF589L and TrkCG623R, respectively. Pan-Trk-IN-3 displays excellent antitumor activity and induces apoptosis.
-
TrkC-IN-1
0 ImagesCat. No.: HY-173227CAS No.: 1877313-32-0TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC. The IC50 values for EBC-1 and HT-29 cells are 3.3-7.1 and 7.3-10.2 μΜ, respectively. TrkC-IN-1 is expected to be used in the research of the anti-cancer field.
-
Type II TRK inhibitor 1
0 ImagesCat. No.: HY-146807CAS No.: 2937543-72-9Type II TRK inhibitor 1 is a potent TRK inhibitor, which inhibits various TRK fusion protein variants and wild type. Type II TRK inhibitor 1 exhibits antiproliferative activity against Ba/F3 cells harboring CD74-TRKAG667C and ETV6-TRKCG696C fusion proteins with IC50s of 6 nM and 1.7 nM, respectively. Type II TRK inhibitor 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
IHMT-TRK-284
0 ImagesCat. No.: HY-146697CAS No.: 2416844-79-4
-
NMS-P626
0 ImagesCat. No.: HY-164514CAS No.: 942471-37-6NMS-P626 is an inhibitor of TRKA, TRKB, and TRKC, with IC50 values of 8 nM, 7 nM, and 3 nM, respectively. NMS-P626 inhibits the growth of KM12 cells by suppressing the phosphorylation of TPM3-TRKA and downstream signaling in KM12 cells, with an IC50 of 19 nM for KM12 cells. NMS-P626 can be used in colorectal cancer research.
- 1
- 2
